ACVC Premium Access

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal PRO.

Presentation

About the speaker

Doctor Andrea Rubboli

Santa Maria delle Croci Hospital, Ravenna (Italy)
12 presentations
0 follower

9 more presentations in this session

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - PRO.

Speaker: Doctor A. Rubboli (Ravenna, IT)

Thumbnail

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - CONTRA.

Speaker: Professor R. Storey (Sheffield, GB)

Thumbnail

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal CONTRA.

Speaker: Professor R. Storey (Sheffield, GB)

Thumbnail

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough: Chairpersons conclusion

Thumbnail

All stented patients with atrial fibrillation, stable one year after intervention, should be managed with oral anticoagulants, without antiplatelets - PRO.

Speaker: Professor R. De Caterina (Pisa, IT)

Thumbnail

Access the full session

Controversies on anticoagulants post-MI antithrombotic treatment

Speakers: Doctor A. Rubboli, Doctor A. Rubboli, Professor R. Storey, Professor R. Storey, Professor R. De Caterina
Thumbnail

About the event

Image

Acute Cardiovascular Care 2018

3 March - 5 March 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk